Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy.

Huang, Chung-Yu; Hsu, Li-Han; Chen, Chung-Yeh; Chang, Gee-Chen; Chang, Hui-Wen; Hung, Yi-Mei; Liu, Ko-Jiunn; Kao, Shu-Huei

Huang, Chung-Yu; Hsu, Li-Han; Chen, Chung-Yeh; Chang, Gee-Chen; Chang, Hui-Wen; Hung, Yi-Mei; Liu, Ko-Jiunn; Kao, Shu-Huei.

Afiliación

Huang CY; Ph.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Hsu LH; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Chen CY; Ph.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Chang GC; Division of Pulmonary and Critical Care Medicine, Sun Yat-Sen Cancer Center, Taipei 11259, Taiwan.
Chang HW; Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
Hung YM; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Liu KJ; Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
Kao SH; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan.

Cancers (Basel) ; 12(1)2020 Jan 10.

Article en En | MEDLINE | ID: mdl-31936895

Palabras clave

EGFR; NSCLC; alternative metabolism; gefitinib-resistant; monocarboxylate transporter 1

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Taiwán